Business Wire

Adtran unlocks full potential of ZR and ZR+ optics with FSP 3000 M-Flex800™

Share

Adtran today launched its FSP 3000 M-Flex800™, enabling network operators to unlock the full potential of ZR and ZR+ optics for high-capacity transport solutions across edge, metro and core networks. This single-slot card – the newest addition to Adtran’s coherent optical technology suite – offers a universal host for ZR and ZR+ optics and addresses many of the shortfalls of IP-over-DWDM (IPoWDM) solutions. Compared to classical OTN muxponder solutions, M-Flex800 supports much simpler demarcation and multiplexing technology. Combined with the use of a wide range of ZR optics, this enables a new way to develop compact and low-power transport solutions from the edge to the core. This new IP-to-DWDM approach enables flexible, cost-efficient networking with separated IP and optical layers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321282596/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s FSP 3000 M-Flex800™ is a one-slot card that acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces. (Photo: Business Wire)

“Initially developed for DCI, ZR optics are now expanding their reach into diverse operational environments. Today’s launch will be key in that transition. Our new FSP 3000 M-Flex800 will be a gateway between classical DWDM and the latest IPoDWDM, bringing the benefits of standardized ZR optics to a broad spectrum of operators,” said Christoph Glingener, CTO of Adtran. “Our versatile one-slot card acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces, seamlessly integrating into any open line system and enabling multiple use cases. Whether you’re looking to deploy in carrier infrastructure or DCI environments, in central offices or street cabinets, our M-Flex800 can be easily slotted into any FSP 3000 chassis.”

The Adtran FSP 3000 M-Flex800 is a versatile, multi-rate line card able to support an extensive range of grey and coherent interfaces, including 100Gbit/s, 400Gbit/s, 800Gbit/s, ZR, ZR+, OpenROADM and other types of coherent optics. Designed to meet the high-capacity connectivity needs of telecom operators, cloud providers and enterprises, it facilitates a range of applications from the edge to the core. This universal host simplifies upgrades to 800Gbit/s line speeds and Ethernet services and can multiplex 100GbE, 400GbE and OTU4 services into line speeds up to 800Gbit/s. Suited for tasks such as IP and optical demarcation, ZR-to-ZR interconnects and edge OTN applications, the Adtran FSP 3000 M-Flex800 offers a cost-effective and low-power solution in a single-slot card.

“With its exceptional flexibility, operational simplicity and compact footprint, our FSP 3000 M-Flex800 caters to diverse environments, from data centers to space-restricted street cabinets. Its ability to reduce power consumption while supporting high-capacity, open and scalable transport is a testament to our commitment to driving the next generation of transport infrastructure,” commented Ryan Schmidt, GM of optical transport at Adtran. “We’re addressing the core needs of network operators across a broad spectrum of applications, even beyond the traditional transponder/muxponder use cases. Today’s launch marks a big step towards more efficient, versatile and cost-effective infrastructure.”

Further information on the FSP 3000 M-Flex800 is available in these slides.

A supporting product video is also available to watch.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye